- Trial phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Why 4/10
- The defining binary catalyst (FDA ANDA approval) has already passed on October 30, 2026. The drug is now approved and the company is transitioning to commercial stage. No further PDUFA or pivotal readout is scheduled for this specific ANDA product in the next ~12 months. The next hard, dated catalyst is the NRX-100 NDA decision for suicidal depression (estimated ~December 2026), but that is a separate regulatory pathway. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
The ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
Price Chart
Executive Summary
NRx Pharmaceuticals (NRXP) received FDA approval for its Preservative-Free Ketamine (KETAFREE) ANDA on October 30, 2026, marking the company's first approved product and its transition from a development-stage biotech to a commercial pharmaceutical company. The drug is a preservative-free formulation of IV ketamine that removes benzethonium chloride (BZT), a toxic preservative found in standard multidose vials. While the approval is a major milestone, the stock fell roughly 15% on the day (a sell-the-news reaction), and the company faces significant commercial execution risk with limited cash, no sales track record, and a pending citizen petition to ban rival BZT-containing products that remains undecided. The next major catalyst is the NRX-100 NDA for suicidal depression, with a PDUFA estimated around late 2026.
How It Works
Ketamine is a well-established generic anesthetic and pain-management drug. NRx's version removes benzethonium chloride (BZT), a preservative found in standard multidose vials that the FDA has not recognized as safe. The drug is administered intravenously and is used for anesthesia, pain management, and increasingly for psychiatric conditions such as treatment-resistant depression.
Trial Status
The FDA approved NRx's Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10 GDUFA goal date. The ANDA pathway relies on demonstrating bioequivalence to the reference listed drug rather than conducting new clinical trials. The company previously received FDA confirmation of bioequivalence, labeling alignment, and completed three commercial-scale manufacturing validation lots with two-year room-temperature stability data.
The Two-Sided Case
Upcoming Catalysts
- Commercial launch and initial sales of Preservative-Free Ketamine / KETAFREE
- FDA decision on NRx's citizen petition to ban BZT-containing ketamine products (pending)
- NRX-100 NDA PDUFA for suicidal depression (estimated ~December 2026)
- Q3 2026 earnings report (scheduled November 16, 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NRx Pharmaceuticals, Inc. Press Release NRXP ·Originating report